Hemangioblastoma is one of the most common primary intra-axial tumors of the posterior fossa, typically presenting as an intensely enhancing mural nodule within a cystic component, classified as WHO grade I, well-circumscribed, and highly vascular neoplasm. Approximately 75% of sporadic cases are located in the cerebellar hemisphere, with a 25-40% association with Von Hippel-Lindau (VHL) syndrome. While more common in adults, VHL-associated cases may present at younger ages and as multiple lesions. The tumor demonstrates intense contrast enhancement due to its rich capillary network and characteristically contains flow voids.
Age Range
20-50
Peak Age
35
Gender
Male predominant
Prevalence
Uncommon
Hemangioblastoma is a WHO grade I tumor composed of stromal cells and a rich capillary vascular network. The stromal cells represent the neoplastic component of the tumor, and mutations in the VHL tumor suppressor gene lead to hyperactivation of the HIF (hypoxia-inducible factor) pathway, resulting in overproduction of VEGF and erythropoietin. This excessive VEGF production explains the tumor's characteristic hypervascularity and intense contrast enhancement; the rich capillary network causes prominent flow voids on MRI. The cystic component forms from accumulation of proteinaceous fluid leaking from tumor vessels, and the true neoplastic portion is only the mural nodule; the cyst wall consists of reactive gliotic tissue. Due to erythropoietin production, 5-20% of patients may develop secondary polycythemia, which serves as a diagnostic clue.
The combination of an intensely homogeneously enhancing mural nodule within a well-circumscribed cystic lesion in the posterior fossa and flow voids within the nodule on T2 is considered pathognomonic for cerebellar hemangioblastoma. This triad — cyst, intensely enhancing nodule, and flow voids — reflects the tumor's vascular nature and WHO grade I biological behavior and is the most reliable finding for differentiating from other posterior fossa tumors such as pilocytic astrocytoma, metastasis, and cystic medulloblastoma.
On non-contrast CT, a well-circumscribed hypodense cystic lesion is seen in the posterior fossa. The mural nodule appears isodense or slightly hyperdense relative to the cyst fluid. The cyst fluid may be slightly hyperdense compared to CSF due to proteinaceous content. Calcification is rare, and if present, alternative diagnoses should be considered. In cases of acute hemorrhage, the mural nodule may appear markedly hyperdense.
Report Sentence
A well-circumscribed cystic lesion is identified in the posterior fossa with a peripherally located isodense/slightly hyperdense mural nodule component.
On contrast-enhanced CT, the mural nodule shows intense homogeneous enhancement, reflecting the tumor's rich capillary vascularity. The cyst wall typically does not enhance, as it contains no neoplastic tissue (reactive gliosis). Enhancement of the cyst wall should raise concern for tumor recurrence or alternative diagnosis. In solid variants, the entire lesion enhances homogeneously. Feeding and draining vessels may be visible on post-contrast images.
Report Sentence
The mural nodule demonstrates intense homogeneous enhancement, with no enhancement of the cyst wall.
On T1-weighted images, the cystic component shows hypointense signal relative to brain parenchyma, but may be slightly hyperintense compared to pure CSF due to proteinaceous content. The mural nodule appears isointense or slightly hypointense to gray matter. In the presence of intratumoral hemorrhage, hyperintense areas may be seen on T1. Flow voids can also be identified as signal void areas on T1 sequences.
Report Sentence
On T1-weighted sequence, the cystic component shows hypointense signal with isointense mural nodule, and flow voids are identified within the nodule.
On T2-weighted images, the cystic component shows markedly hyperintense signal (CSF-like, but usually slightly different from CSF due to proteinaceous content). The mural nodule demonstrates intermediate to hyperintense signal with characteristic flow voids within it; these flow voids are pathognomonic for the tumor's hypervascular nature. Variable vasogenic edema may be present in the surrounding parenchyma. The presence of flow voids on T2 is critical for differentiating from other cystic posterior fossa tumors such as pilocytic astrocytoma.
Report Sentence
On T2-weighted sequence, the cystic component is markedly hyperintense, the mural nodule shows intermediate-hyperintense signal with prominent flow voids within the nodule indicating hypervascularity.
On FLAIR, the cyst fluid typically does not fully suppress and appears slightly hyperintense compared to CSF; this results from proteinaceous content shortening T1 time and is an important finding for differentiating from arachnoid cyst. The mural nodule appears slightly hyperintense relative to surrounding parenchyma. Perilesional vasogenic edema can be seen as markedly hyperintense on FLAIR. Findings of obstructive hydrocephalus may accompany large lesions.
Report Sentence
On FLAIR, the cyst fluid does not fully suppress and appears slightly hyperintense compared to CSF, indicating proteinaceous content and having diagnostic value in differentiating from simple arachnoid cyst.
On diffusion-weighted imaging (DWI), neither the cystic component nor the mural nodule shows true diffusion restriction. The cyst fluid may show T2 shine-through effect on DWI but does not demonstrate low signal on ADC map — ADC values are high (free water diffusion). This finding is critical for differentiating from pathologies showing diffusion restriction such as epidermoid cyst and abscess. The mural nodule does not show significant diffusion restriction due to its low-intermediate cellularity.
Report Sentence
On diffusion-weighted imaging, no true diffusion restriction is detected in the cystic component or mural nodule; high signal is noted on ADC map.
On post-gadolinium T1-weighted images, the mural nodule shows intense homogeneous enhancement — one of the most characteristic findings of hemangioblastoma. Signal voids (flow voids) are identified within the enhancing nodule, revealing the tumor's hypervascular nature. The cyst wall typically does not enhance; enhancement if present should be evaluated for tumor recurrence. Feeding artery and draining vein may be prominently visible on contrast sequences. In solid variants, the lesion enhances homogeneously and intensely.
Report Sentence
On post-contrast T1-weighted sequence, the mural nodule demonstrates intense homogeneous enhancement with flow voids identified within the nodule; no enhancement of the cyst wall is detected.
On perfusion MRI (DSC or DCE), markedly elevated relative cerebral blood volume (rCBV) is detected in the mural nodule; this value is typically 5-10 times or more than normal brain parenchyma. High rCBV reflects the tumor's rich capillary network and VEGF-mediated neoangiogenesis. No perfusion increase is seen in the cystic component. This finding creates a striking contrast with low rCBV in low-grade gliomas and demonstrates that hemangioblastoma shows high vascularity despite being WHO grade I.
Report Sentence
On perfusion MRI, markedly elevated rCBV values are detected in the mural nodule, consistent with the hypervascular nature of the tumor.
On susceptibility weighted imaging (SWI), prominent flow voids and intratumoral vascular structures are identified within the mural nodule. Feeding artery and draining vein become conspicuous with low signal (blooming) on SWI. Areas of intratumoral hemorrhage may create additional foci of low signal due to hemosiderin deposition. SWI demonstrates vascular structures and hemorrhagic products much more sensitively compared to conventional sequences.
Report Sentence
On SWI, prominent flow voids and intratumoral vascular structures are identified within the mural nodule, with feeding and draining vessels visualized.
On MR spectroscopy (MRS), a prominent lipid peak (1.3 ppm) is observed in the mural nodule, reflecting the lipid-rich stromal cells within the tumor. N-acetylaspartate (NAA) peak is reduced or absent because the tumor does not contain neuronal tissue. Choline peak is variable and generally does not show prominent elevation compared to high-grade tumors. Lactate peak may be present. This spectral profile differs from high-grade gliomas (prominent choline elevation) and metastases (prominent lipid + elevated choline).
Report Sentence
On MR spectroscopy, a prominent lipid peak is detected in the mural nodule with reduced NAA peak and variable choline levels.
Criteria
Large cystic component (60-70% volume) with a small, intensely enhancing mural nodule. Most common form (60-70%). Mural nodule is typically attached to one edge of the cyst wall and contains flow voids.
Distinct Features
Cyst wall does not enhance (reactive gliosis, non-neoplastic). Surgically, removal of the mural nodule is sufficient, cyst wall resection is not required. Recurrence rate is low (10-20%).
Criteria
Entirely solid lesion without cystic component or with minimal cystic change. Constitutes 30-40% of cases. The entire lesion shows intense homogeneous enhancement. Flow voids may also be seen within the solid lesion.
Distinct Features
Differentiation from pilocytic astrocytoma and metastasis may be more difficult. Very high rCBV on perfusion MRI is more prominent in solid type and carries diagnostic value. Preoperative embolization may be considered in surgical planning.
Criteria
Multiple hemangioblastomas developing in the setting of Von Hippel-Lindau syndrome. CNS hemangioblastomas develop in 60-80% of VHL patients. May be located in cerebellum, brainstem, and spinal cord. Earlier age of onset (20-30 years).
Distinct Features
Combination of multiple CNS lesions + retinal angiomas + renal cell carcinoma + pheochromocytoma suggests VHL. Regular imaging follow-up is required. New lesions may appear over years. Genetic counseling and family screening is recommended.
Criteria
Spinal cord-located hemangioblastoma, may be intramedullary or intradural extramedullary. Constitutes 3-13% of all hemangioblastomas. More common in VHL patients. Most frequently seen in thoracic and cervical segments.
Distinct Features
Associated syringomyelia is common. Diagnosis is made with intensely enhancing nodule and flow voids on contrast MRI. Preoperative spinal angiography demonstrates feeding vessels. Intense enhancement and flow voids are distinguishing features from ependymoma and astrocytoma.
Distinguishing Feature
Pilocytic astrocytoma can also present as cystic with mural nodule, but flow voids are not seen in the mural nodule, rCBV on perfusion MRI is significantly lower than hemangioblastoma, and it occurs more frequently in children.
Distinguishing Feature
Metastasis can have a cystic component but typically shows no flow voids in mural nodule, perilesional edema is more pronounced, usually multiple with known primary malignancy history, and cyst wall may enhance.
Distinguishing Feature
Medulloblastoma is a midline (vermis) posterior fossa solid dominant tumor showing marked diffusion restriction on DWI (high cellularity), no flow voids, more common in childhood, and tends to spread via CSF dissemination.
Distinguishing Feature
Arachnoid cyst follows CSF signal on all sequences (complete suppression on FLAIR), shows no enhancement, contains no mural nodule or solid component, and shows no restriction on DWI; hemangioblastoma cystic component does not fully suppress on FLAIR.
Distinguishing Feature
Ependymoma arises from the 4th ventricle in the posterior fossa, tends to extend through the foramen magnum (plastic growth), may show calcification and cystic changes but flow voids are rare, enhances heterogeneously, and does not show the intense vascularity seen in hemangioblastoma.
Urgency
semi-urgentManagement
surgicalBiopsy
Not NeededFollow-up
Annual MRI for VHL patients; post-surgical MRI at 3 months then annually for 5 yearsHemangioblastoma is a WHO grade I tumor and surgical resection is curative. Complete resection of the mural nodule is sufficient and cyst wall removal is not required. Preoperative embolization may reduce intraoperative bleeding for large and solid tumors. VHL syndrome screening (genetic testing, retinal examination, abdominal imaging) is recommended even in sporadic cases. Lifelong regular follow-up is necessary in VHL-associated patients. Biopsy is contraindicated — high risk of serious hemorrhage due to high vascularity. Stereotactic radiosurgery (SRS) may be an alternative for recurrent or multiple lesions.
Hemangioblastoma is surgically curable — complete resection of the mural nodule is sufficient (cyst wall removal not necessary). In suspected VHL syndrome, genetic testing and systemic screening (retinal hemangioblastoma, pheochromocytoma, renal cell carcinoma, pancreatic cysts) are required. Prognosis in sporadic cases is excellent.